This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in patients with intracranial tumors that have come back. Imaging agents, such as fluoroethyltyrosine, may help doctors see the tumor better during a positron emission tomography PET scan.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04044937.
PRIMARY OBJECTIVES:
I. To determine if F-18 fluoroethyltyrosine (FET) PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1.
II. To determine if FET PET can accurately differentiate between low-grade and high-grade gliomas in population 2.
SECONDARY OBJECTIVES:
I. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology or imaging follow-up in population 1.
II. To determine if FET PET can differentiate between benign treatment-related changes and recurrence in comparison to pathology alone in population 1 patients with recurrent low-grade gliomas (grades 1 and 2).
EXPLORATORY OBJECTIVES:
I. To assess relationships between serial FET PET and clinical outcome (benign treatment-related changes and recurrence) in patients with recurrent metastatic lesion, recurrent high grade gliomas and recurrent low grade gliomas.
II. To determine if MRI can differentiate between benign treatment- related changes and recurrence.
OUTLINE:
Patients receive F-18 fluoroethyltyrosine intravenously (IV) over approximately 1 minute and undergo PET over 40 minutes. Adult patients may undergo an additional FET PET.
After completion of study treatment, patients are followed up periodically.
Lead OrganizationUniversity of California San Francisco
Principal InvestigatorThomas A. Hope
